Athira Pharma Past Earnings Performance
Past criteria checks 0/6
Athira Pharma's earnings have been declining at an average annual rate of -42.8%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-42.8%
Earnings growth rate
-16.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -189.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?
Feb 16
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
Nov 02Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?
May 29Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
Jan 04Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis
Oct 17Athira Pharma GAAP EPS of -$0.65
Aug 15We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Aug 09Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug
Jun 22Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth
May 08We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate
Jan 11Athira Pharma: What, Exactly, Did The CEO Do?
Jun 29Athira Pharma falls after the decision to place CEO on temporary leave
Jun 17Athira surges after Jefferies estimated 50% gain on FDA approval for Biogen’s Alzheimer’s therapy
Jun 07We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth
May 24We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely
Feb 08
Athira: Early Stage Alzheimer's Therapeutics With An Interesting Approach
Jan 11Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like
Dec 18Athira Pharma nabs research grant of $15M from NIH
Dec 08Athira Pharma reports Q3 results
Nov 12Revenue & Expenses Breakdown
How Athira Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -109 | 27 | 85 |
| 30 Jun 24 | 0 | -113 | 27 | 94 |
| 31 Mar 24 | 0 | -116 | 31 | 94 |
| 31 Dec 23 | 0 | -118 | 33 | 94 |
| 30 Sep 23 | 0 | -121 | 34 | 85 |
| 30 Jun 23 | 0 | -108 | 33 | 75 |
| 31 Mar 23 | 0 | -102 | 32 | 68 |
| 31 Dec 22 | 0 | -96 | 33 | 61 |
| 30 Sep 22 | 0 | -82 | 31 | 59 |
| 30 Jun 22 | 0 | -77 | 31 | 53 |
| 31 Mar 22 | 0 | -67 | 27 | 50 |
| 31 Dec 21 | 0 | -55 | 21 | 43 |
| 30 Sep 21 | 0 | -46 | 19 | 35 |
| 30 Jun 21 | 0 | -39 | 13 | 30 |
| 31 Mar 21 | 0 | -27 | 9 | 20 |
| 31 Dec 20 | 0 | -20 | 7 | 13 |
| 30 Sep 20 | 0 | -13 | 3 | 9 |
| 30 Jun 20 | 0 | -6 | 2 | 4 |
| 31 Mar 20 | 0 | -6 | 2 | 3 |
| 31 Dec 19 | 0 | -5 | 2 | 4 |
Quality Earnings: ATHA is currently unprofitable.
Growing Profit Margin: ATHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ATHA is unprofitable, and losses have increased over the past 5 years at a rate of 42.8% per year.
Accelerating Growth: Unable to compare ATHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ATHA has a negative Return on Equity (-189.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 08:36 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Athira Pharma, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Esther Lannie Hong | Berenberg |
| Thomas Shrader | BTIG |
| Corinne Johnson | Goldman Sachs |